Search Results
Jun 09, 2026, 08:13 ET Sub-Nanometer Accuracy, Zero Friction: Next-Generation Air Bearing Linear Slide
±0.25 µm — a level of geometric performance unachievable with recirculating ball or crossed-roller mechanical bearing stages.Air Bearings vs. Mechanical Bearing StagesUnlike mechanical bearing stages, which rely on rolling or sliding contact that introduces friction, stiction,
More news about: Physik Instrumente (PI)
Jun 09, 2026, 08:05 ET TalentLMS Speed-to-Skill Report: Work Is Changing Faster Than Companies Can Build Skills
last year, compared to 10% of employees. Managers are also more than twice as likely as employees to say this happened within the last six months (12% vs. 5%).Yet only 16% of respondents say skill-building happens quickly whenever new needs arise in their company, even as 70% agree employees need
More news about: TalentLMS
Jun 09, 2026, 08:00 ET #WalkAway Campaign Announces Two-Part Release of "The Great MAGA Divide Debate: America First vs. MAGA"
Following the major response to "Baby Boomers vs. Millennials," Brandon Straka and #WalkAway continue the viral debate series with a new two-part conversation exploring the future of the MAGA and America First movements.NEW YORK, June
More news about: #WalkAway
Jun 09, 2026, 08:00 ET New Research Reveals the More Confident Organizations Are in Their AI Security, the More Likely They've Already Been Breached
confirmed incident80% report shadow AI (employees connecting AI tools without security or IT review)83% vs 38% confirmed incident rate for multi-tenant SaaS vs. self-hosted identity platforms85% have faced customer, partner, or regulatory demands to prove tenant isolation93% say
More news about: FusionAuth
Jun 09, 2026, 07:00 ET The J.M. Smucker Co. Announces Fiscal Year 2026 Fourth Quarter Results and Provides Full-Year Fiscal 2027 Outlook
Net sales decrease vs. prior year
More news about: The J.M. Smucker Co.
Jun 09, 2026, 06:00 ET CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™
Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.Bergenstal R., et al Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles; Journal of Diabetes Science and Technology 1–7,
More news about: CeQur Corporation
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
informative than maximum weight lost for subsequent incident risk across a broad spectrum of brain and behavior outcomes.In the study "Functional-vs-Cognitive Decline Heterogeneity in Alzheimer's Disease Revealed by LLM-curation of Decades of Clinical Notes has Implications for Semaglutide Trial
More news about: nference
Jun 09, 2026, 02:00 ET SEL Develops High-energy-density Lithium-ion Rechargeable Battery Having Fire Resistance, Using Novel Cathode Material LCNO (TM) (Ni-doped LCO)
material, is known to deteriorate due to repeated charging and discharging. General LCO undergoes a phase transition to the H1-3 phase (*5) around 4.55 V (vs. Li+/Li) during charging (when Li is extracted from LCO). As a result, the CoO2 layers shift, making it impossible to return to its original state (O3
More news about: Semiconductor Energy Laboratory Co., Ltd.
Jun 08, 2026, 22:38 ET Global Football Tournament Drives Travel Surge, with Group Stage Booking Growth Nearly Double Knockout Round's: Trip.com Data
dominate, with travellers focusing on 1 or more cities within a single North American country.Lead Times and Loyalty: The Forward Planners vs. The Late DecidersThe gap in booking behaviour between the Group Stage and the Knockout Round is fascinating. Travelling fans booking for July,
More news about: Trip.com
Jun 08, 2026, 14:30 ET ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small-Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions
occurrence of gastrointestinal symptoms and a slightly greater increase in heart rate. A1C was reduced by 1.9% vs. 1.5%, and body weight was reduced by 8.2% vs 5.3% with orforglipron 36 mg vs. oral semaglutide 14mg, respectively."The findings support orforglipron as a potential new oral GLP-1
More news about: American Diabetes Association
Jun 08, 2026, 14:30 ET Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
37.1%i,iiip<0.001 vs. oral semaglutide 7 mgiip<0.001 vs. oral semaglutide 14 mgiiip<0.01 vs. oral semaglutide 14 mgivBody weight for Foundayo 9 mg vs. oral semaglutide 14 mg and percentage
More news about: Eli Lilly and Company
Jun 08, 2026, 13:43 ET Urinary Tract Infection Testing Market to Reach USD 78.9 Billion by 2036 as Rapid Diagnostics and Antibiotic Stewardship Drive Global Adoption | Future Market Insights
https://www.futuremarketinsights.com/customization-available/rep-gb-10134Production vs. Consumption Economy AnalysisNorth America and Europe continue to lead adoption of advanced UTI diagnostic technologies due to established
More news about: Future Market Insights
Jun 08, 2026, 11:02 ET In HelloNation, Insurance Expert Joseph Puckett Explains How to Choose Between Term Life and Whole Life Insurance
Term Life vs. Whole Life: Choosing the Right Protection features insights from Joseph Puckett, Insurance Expert of Bedford, Texas, in HelloNation.About
More news about: HelloNation
Jun 08, 2026, 10:01 ET High-performance Fiber Market to Reach USD 43.4 Billion by 2036 as Aerospace Lightweighting and Electric Vehicle Adoption Accelerate Global Demand
production capacity additions, and recycled composite technologies are expected to remain key competitive differentiators through 2036.Production vs. Consumption Economy AnalysisProduction remains concentrated within Japan, China, the United States, Germany, and South Korea, supported by
More news about: Future Market Insights
Jun 08, 2026, 09:30 ET EDGE Markets Raises $29.2 Million Series A Funding Round
directly through their EDGE Pro accounts and conduct post-execution settlement across various liquidity pools to dramatically amplify capital efficiencies vs. the current model where all trading accounts need to be prefunded and fully collateralized. Finally, EDGE Pro users will be able to plug and play existing
More news about: EDGE Markets
Jun 08, 2026, 09:30 ET EDGE Markets Raises $29.2 Million Series A Funding Round
directly through their EDGE Pro accounts and conduct post-execution settlement across various liquidity pools to dramatically amplify capital efficiencies vs. the current model where all trading accounts need to be prefunded and fully collateralized. Finally, EDGE Pro users will be able to plug and play existing
More news about: EDGE Markets
Jun 08, 2026, 09:05 ET LYSOL® DECLARES JULY 5TH "ADDRESS THE MESS" DAY, AS TWO-THIRDS OF U.S. ADULTS SAY THEY LOSE TIME TO CLEANING DURING CELEBRATIONS
https://www.feedingamerica.org/*When used as directed**Lysol proven to kill the SARS-CoV-2 virus in 15-seconds and expected to have similar efficacy vs all strains and variants (
More news about: Lysol
Jun 08, 2026, 08:31 ET MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
body weight at Day 26 and a 9.1% reduction at Day 54 (p<0.05 vs placebo at Day 26), with continued reductions through Week 8 and no evidence of plateau. Waist circumference was reduced by 5.8 cm at Day 22 and 9.8 cm at Day 54 (p<0.05 vs placebo), with accompanying reductions in BMI of 2.3 kg/m² and
More news about: MetaVia Inc.
Jun 08, 2026, 08:05 ET THERABODY LAUNCHES CRYOTHERM™ PALM, ITS FIRST THERMOREGULATION PERFORMANCE DEVICE, BRINGING SCIENCE-BACKED PALM COOLING TO MANAGE HEAT ON SPORT'S BIGGEST STAGE
volume during resistance training vs. control*58% more reps in the final set vs. control*7% increase in post-session grip strength vs. control*Athletes felt 60% cooler during repeated sprint efforts**2.45% increase in top sprint speed vs. control**4.7% better
More news about: Therabody
Jun 08, 2026, 08:05 ET THERABODY LAUNCHES CRYOTHERM™ PALM, ITS FIRST THERMOREGULATION PERFORMANCE DEVICE, BRINGING SCIENCE-BACKED PALM COOLING TO MANAGE HEAT ON SPORT'S BIGGEST STAGE
volume during resistance training vs. control*58% more reps in the final set vs. control*7% increase in post-session grip strength vs. control*Athletes felt 60% cooler during repeated sprint efforts**2.45% increase in top sprint speed vs. control**4.7% better
More news about: Therabody
Jun 08, 2026, 08:02 ET EPAM and TGS Announce Strategic Collaboration to Accelerate AI Adoption at Scale in Energy Sector
EPAM on AWS, will deliver benchmarked performance gains on select seismic imaging workflows through AWS Graviton-based instances and cost reductions vs on-demand pricing using AWS Spot generic instances.Composable Workflows and AI Enablement – EPAM's Energy HPC Orchestrator
More news about: EPAM Systems, Inc.
Jun 08, 2026, 08:00 ET Vasa Therapeutics to Deliver Two Presentations on VS-041 at ECM2026, Featuring Preclinical and First-in-Human Data and Ongoing Phase 1c Trial Design in HFpEF
Chief Medical Officer, will deliver two presentations on VS-041 at ECM2026, the Extracellular Matrix Pharmacology Conference, to be held June 14-17, 2026, in Copenhagen, Denmark. Dr. Henig will present preclinical and first-inhuman clinical data on VS-041 in an oral presentation and will describe the rationale
More news about: Vasa Therapeutics
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
(median DOR 37 vs 6 months; duration of complete response (DOCR) NR vs 11 months, respectively) and time to next treatment (TTNT) (7 vs 4 months, respectively; nominal P value <0.0001).2Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
(median DOR 37 vs 6 months; duration of complete response (DOCR) NR vs 11 months, respectively) and time to next treatment (TTNT) (7 vs 4 months, respectively; nominal P value <0.0001).2Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported
More news about: AbbVie
Jun 08, 2026, 08:00 ET Hospice Care And Palliative Care Differences Explained In HelloNation Featuring Hospice Care Expert Tammy Honeycutt
Hospice vs Palliative Care in Metro Atlanta: Key Differences Explained features insights from Tammy Honeycutt, Hospice Care Expert of Social Circle, Georgia,
More news about: HelloNation